ZA202101051B - Antibodies binding to citrullinated histone 2a and/or 4 - Google Patents
Antibodies binding to citrullinated histone 2a and/or 4Info
- Publication number
- ZA202101051B ZA202101051B ZA2021/01051A ZA202101051A ZA202101051B ZA 202101051 B ZA202101051 B ZA 202101051B ZA 2021/01051 A ZA2021/01051 A ZA 2021/01051A ZA 202101051 A ZA202101051 A ZA 202101051A ZA 202101051 B ZA202101051 B ZA 202101051B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibodies binding
- citrullinated histone
- citrullinated
- histone
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813597.0A GB201813597D0 (en) | 2018-08-21 | 2018-08-21 | Antibody |
| GBGB1900983.6A GB201900983D0 (en) | 2019-01-24 | 2019-01-24 | Antibody |
| PCT/EP2019/072302 WO2020038963A1 (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202101051B true ZA202101051B (en) | 2022-08-31 |
Family
ID=67688785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/01051A ZA202101051B (en) | 2018-08-21 | 2021-02-16 | Antibodies binding to citrullinated histone 2a and/or 4 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20210395350A1 (https=) |
| EP (2) | EP3841120B1 (https=) |
| JP (2) | JP7434328B2 (https=) |
| KR (2) | KR102871821B1 (https=) |
| CN (2) | CN120058926A (https=) |
| AU (3) | AU2019326740B2 (https=) |
| CA (1) | CA3110013A1 (https=) |
| DK (1) | DK3841120T3 (https=) |
| ES (1) | ES3048210T3 (https=) |
| FI (1) | FI3841120T3 (https=) |
| HR (1) | HRP20251346T1 (https=) |
| IL (2) | IL280995B2 (https=) |
| LT (1) | LT3841120T (https=) |
| MX (3) | MX2025007881A (https=) |
| PT (1) | PT3841120T (https=) |
| RS (1) | RS67385B1 (https=) |
| SG (1) | SG11202101652PA (https=) |
| SI (1) | SI3841120T1 (https=) |
| SM (1) | SMT202500388T1 (https=) |
| WO (1) | WO2020038963A1 (https=) |
| ZA (1) | ZA202101051B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| AU2016303688B2 (en) | 2015-07-31 | 2023-06-15 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| WO2020038963A1 (en) | 2018-08-21 | 2020-02-27 | Modiquest B.V. | Antibodies binding to citrullinated histone 2a and/or 4 |
| SG11202103001PA (en) | 2018-10-05 | 2021-04-29 | Res Inst Nationwide Childrens Hospital | Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application |
| WO2021209465A1 (en) * | 2020-04-14 | 2021-10-21 | Universiteit Maastricht | Peptide for the treatment of net-associated diseases |
| CN116096239B (zh) * | 2020-07-07 | 2025-09-02 | 国家儿童医院研究所 | 治疗和预防生物膜的联合疗法 |
| GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
| WO2022233931A1 (en) | 2021-05-04 | 2022-11-10 | Citryll B.V. | Inhibition of eosinophilic traps |
| EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
| EP4442705A1 (en) | 2023-04-03 | 2024-10-09 | Citryll B.V. | Dosage |
| GB202318703D0 (en) * | 2023-12-07 | 2024-01-24 | Citryll B V | Diagnostic agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| AU2009253923B2 (en) | 2008-06-04 | 2014-02-13 | Citryll B.V. | Anti-inflammatory agents |
| HRP20170374T1 (hr) | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biološki proizvodi |
| US20120283415A1 (en) | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
| EP2332987A1 (en) * | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
| GB201410520D0 (en) * | 2014-06-12 | 2014-07-30 | Univ London Queen Mary | Antibody |
| US11066462B2 (en) * | 2014-12-11 | 2021-07-20 | Citryll B.V. | Method for the treatment of idiopathic pulmonary fibrosis |
| US20170038381A1 (en) * | 2015-08-06 | 2017-02-09 | Novimmune Sa | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| WO2020038963A1 (en) | 2018-08-21 | 2020-02-27 | Modiquest B.V. | Antibodies binding to citrullinated histone 2a and/or 4 |
| WO2022233931A1 (en) | 2021-05-04 | 2022-11-10 | Citryll B.V. | Inhibition of eosinophilic traps |
| CN117396221A (zh) * | 2021-05-04 | 2024-01-12 | 奇特里尔私人有限公司 | 嗜酸性粒细胞陷阱的抑制 |
-
2019
- 2019-08-20 WO PCT/EP2019/072302 patent/WO2020038963A1/en not_active Ceased
- 2019-08-20 CN CN202510240710.XA patent/CN120058926A/zh active Pending
- 2019-08-20 EP EP19756180.6A patent/EP3841120B1/en active Active
- 2019-08-20 AU AU2019326740A patent/AU2019326740B2/en active Active
- 2019-08-20 ES ES19756180T patent/ES3048210T3/es active Active
- 2019-08-20 RS RS20251114A patent/RS67385B1/sr unknown
- 2019-08-20 EP EP25196231.2A patent/EP4659807A3/en active Pending
- 2019-08-20 CN CN201980070130.3A patent/CN112930356B/zh active Active
- 2019-08-20 KR KR1020217008362A patent/KR102871821B1/ko active Active
- 2019-08-20 DK DK19756180.6T patent/DK3841120T3/da active
- 2019-08-20 IL IL280995A patent/IL280995B2/en unknown
- 2019-08-20 SI SI201930975T patent/SI3841120T1/sl unknown
- 2019-08-20 FI FIEP19756180.6T patent/FI3841120T3/fi active
- 2019-08-20 JP JP2021534820A patent/JP7434328B2/ja active Active
- 2019-08-20 MX MX2025007881A patent/MX2025007881A/es unknown
- 2019-08-20 KR KR1020257029356A patent/KR20250148711A/ko active Pending
- 2019-08-20 HR HRP20251346TT patent/HRP20251346T1/hr unknown
- 2019-08-20 SM SM20250388T patent/SMT202500388T1/it unknown
- 2019-08-20 LT LTEPPCT/EP2019/072302T patent/LT3841120T/lt unknown
- 2019-08-20 PT PT197561806T patent/PT3841120T/pt unknown
- 2019-08-20 CA CA3110013A patent/CA3110013A1/en active Pending
- 2019-08-20 US US17/269,509 patent/US20210395350A1/en not_active Abandoned
- 2019-08-20 SG SG11202101652PA patent/SG11202101652PA/en unknown
- 2019-08-20 IL IL322482A patent/IL322482A/en unknown
- 2019-08-20 MX MX2021001902A patent/MX2021001902A/es unknown
-
2021
- 2021-02-16 ZA ZA2021/01051A patent/ZA202101051B/en unknown
- 2021-02-17 MX MX2025007882A patent/MX2025007882A/es unknown
- 2021-07-06 US US17/368,720 patent/US11345750B2/en active Active
-
2022
- 2022-05-27 US US17/827,488 patent/US12590143B2/en active Active
-
2024
- 2024-02-06 JP JP2024016700A patent/JP7835788B2/ja active Active
-
2026
- 2026-02-20 AU AU2026201302A patent/AU2026201302A1/en active Pending
- 2026-02-20 AU AU2026201303A patent/AU2026201303A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202101051B (en) | Antibodies binding to citrullinated histone 2a and/or 4 | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| IL278924A (en) | Antibodies specific to GUCY2C and their uses | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
| ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| SG11202101675UA (en) | Anti-bcma single domain antibodies and application thereof | |
| IL278466B1 (en) | Anti-dll3 antibodies and uses thereof | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| ZA202100714B (en) | Anti-npr1 antibodies and uses thereof | |
| IL287816A (en) | Tigit antibody and its use | |
| IL321888B1 (en) | Antibodies that bind 1-PD and their uses | |
| IL282707A (en) | Anti-tim-3 antibodies and their use | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| SG11202105161YA (en) | Anti-il-27 antibodies and uses thereof | |
| IL282708A (en) | Anti-tim-3 antibodies and their use | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL283890A (en) | Anti-periostin antibodies and their uses |